Hikma Pharmaceuticals (LON:HIK) Trading Down 14.1% – What’s Next?

Shares of Hikma Pharmaceuticals PLC (LON:HIK) traded down 14.1% on Thursday . The stock traded as low as GBX 1,522 and last traded at GBX 1,522. 166,325,172 shares traded hands during trading, an increase of 7,989% from the average session volume of 2,056,107 shares. The stock had previously closed at GBX 1,771.

Analysts Set New Price Targets

A number of research firms recently issued reports on HIK. Berenberg Bank dropped their price target on shares of Hikma Pharmaceuticals from GBX 2,560 to GBX 2,510 and set a “buy” rating on the stock in a research note on Thursday, October 16th. Jefferies Financial Group reissued a “buy” rating and set a GBX 2,600 target price on shares of Hikma Pharmaceuticals in a research note on Thursday, August 7th. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a “buy” rating on the stock in a research note on Tuesday, August 12th. Finally, JPMorgan Chase & Co. cut their price objective on Hikma Pharmaceuticals from GBX 2,600 to GBX 2,500 and set an “overweight” rating for the company in a research note on Friday, August 8th. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of GBX 2,615.

Hikma Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 55.82, a quick ratio of 1.27 and a current ratio of 1.66. The firm’s 50-day moving average price is GBX 1,740.80 and its two-hundred day moving average price is GBX 1,898.69. The stock has a market cap of £3.37 billion, a price-to-earnings ratio of 9.11, a PEG ratio of 2.38 and a beta of 0.41.

Insider Transactions at Hikma Pharmaceuticals

In related news, insider Mazen Darwazah acquired 14,000 shares of the firm’s stock in a transaction dated Tuesday, September 16th. The shares were purchased at an average cost of GBX 1,603 per share, for a total transaction of £224,420. Also, insider Laura Balan Balan bought 3,500 shares of the company’s stock in a transaction that occurred on Friday, August 22nd. The stock was bought at an average price of GBX 1,821 per share, with a total value of £63,735. 17.77% of the stock is currently owned by company insiders.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.